molecules of the month


once daily, oral THR β-selective agonist

Ph. III for NASH

opt. of triiodothyronine

Lancet, December 17, 2022

Madrigal Pharmaceuticals, West Conshohocken, PA

resmetirom chemical structure once daily, oral THR β-selective agonist - Madrigal Pharmaceuticals, West Conshohocken
5 mins read

A first-in-class drug for NASH? Resmetirom, an oral, liver-targeting, once-daily THR-β-selective agonist, recently made headlines for meeting both primary surrogate endpoints in an early Ph. III readout for NASH, demonstrating NASH resolution and no worsening of fibrosis by biopsy after 52 weeks in 26% of patients at 80 mg QD (n=316) vs. 10% for placebo (n=318), and demonstrating improvement in fibrosis with no worsening of NASH (24% at 80 mg vs. 14% for placebo). These unexpectedly positive results skyrocketed the valuation of Madrigal (MDGL) to over $5B. Resmetirom could become the first drug to achieve accelerated approval for NASH, with an NDA to be filed in ‘23. Why is this a big deal? Non-alcoholic steatohepatitis (NASH) impacts an estimated 3-5% of…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: